Opinion|Videos|September 3, 2024
ASCERTAIN Data: Oral Decitabine-Cedazuridine Outcomes in MDS
Medical experts discuss the data gathered from the ASCERTAIN trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Although oral decitabine-cedazuridine has been FDA approved for some time, the ASCERTAIN trial data are a recent advancement in our knowledge of this drug and its use in myelodysplastic syndromes (MDS). Briefly describe the ASCERTAIN trial design.
- What are some key takeaways regarding the outcomes of treating MDS with oral decitabine-cedazuridine compared with intravenous decitabine, according to the ASCERTAIN data?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Cicada COVID-19 Variant FAQs: Symptoms, Risk, and Prevention
2
INHALE-1 Findings Support Inhaled Insulin as a Viable Option for Pediatric Patients: Kevin Kaiserman, MD
3
AI Reshaping Diabetes Care From Nutrition to Clinical Decisions
4
Social Factors Shape Diabetes, Dementia Risk Across Populations
5